FGFR1Pred: an artificial intelligence-based model for predicting fibroblast growth factor receptor 1 inhibitor

Ekambarapu Sree Charan1, Anju Sharma1, Hardeep Sandhu1

  • 1Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, S. A. S. Nagar, Mohali, Punjab, 160 062, India.

Molecular Diversity
|August 11, 2023
PubMed

Insights

Artificial intelligence (AI) accelerates the discovery of fibroblast growth factor receptor 1 (FGFR1) inhibitors. An AI model accurately predicts potential FGFR1 inhibitors, aiding cancer drug development and reducing costs.

Area of Science:

  • Computational chemistry and bioinformatics
  • Drug discovery and medicinal chemistry
  • Oncology and molecular biology

Background:

  • Fibroblast growth factor receptors (FGFRs), particularly FGFR1, are crucial in various cellular functions and implicated in numerous cancers.
  • Overactive FGFR1 signaling drives cancer cell proliferation and survival, making it a promising therapeutic target.
  • Traditional methods for discovering FGFR1 inhibitors are costly, time-consuming, and labor-intensive.

Purpose of the Study:

  • To develop artificial intelligence (AI)-based prediction models for identifying potential fibroblast growth factor receptor 1 (FGFR1) inhibitors.
  • To accelerate the drug discovery process by efficiently exploring chemical space and reducing costs.
  • To provide a valuable tool for identifying novel FGFR1 inhibitors for therapeutic development.

Main Methods:

  • Utilized a dataset of 2356 chemical compounds to train AI-based prediction models.
  • Employed four machine learning (ML) algorithms: Support Vector Machine (SVM), Random Forest (RF), k-Nearest Neighbors (k-NN), and Artificial Neural Network (ANN).
  • Models were trained using molecular descriptors (1D and 2D, with and without molecular fingerprints).

Main Results:

  • The Random Forest (RF)-based prediction model demonstrated the highest accuracy: 98.9% on the training dataset, 89.8% on the test dataset, and 90.3% on the external test dataset.
  • The developed AI model, named FGFR1Pred, effectively predicts potential FGFR1 inhibitors.
  • The model is publicly available to facilitate further research and drug discovery.

Conclusions:

  • AI-based prediction models, particularly the RF model, offer a powerful and efficient approach for identifying FGFR1 inhibitors.
  • FGFR1Pred accelerates the drug discovery pipeline, potentially leading to the development of new cancer therapeutics.
  • This AI tool aids in exploring vast chemical spaces for drug candidates, reducing the time and cost associated with traditional methods.